title: Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells.
abstract: OBJECTIVE
  To assess the role of endogenous lactoferrin (LF) in the formation of the molecular phenotype of human breast cancer (BC) cell lines with varying degrees of malignancy, including cisplatin/doxorubicin resistant cell lines, and identify possible impact of exogenous LF.
  
  
  METHODS
  5 breast cell lines of different origin - MCF-10 A, MCF-7, including doxorubicin/cisplatin resistant ones, T47D, MDA-MB-231, and MDA-MB-468. Immunocytochemistry: expression of LF, Ki-67, adhesion molecules E- and N-cadherin, CD44, CD24 rating the invasive potential of cells.
  
  
  RESULTS
  Expression of LF in human BC cell lines varies. It is associated with the heterogeneity of molecular profiles of cell lines in terms of adhesion. A link has been established between the level of LF expression in the resistant cell line MCF-7/CP and MCF-7/Dox, features of their molecular profile and invasive properties. Exogenous LF was shown to be capable of modifying the molecular profile and invasive properties of all the studied cell lines including resistant ones (MCF-7/CP and MCF-7/Dox).
  
  
  CONCLUSIONS
  The sensitivity of cytostatic-resistant cell lines (MCF-7/CP and MCF-7/Dox) tends to increase under the influence of exogenous LF. It is likely that this effect is due to LF-mediated inhibition of the expression of proteins associated with drug resistance.
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: V F
authors.initials: VF
authors.lastname: Chekhun
authors.affiliation: State Scientific Institution "Institute of Physiology", NAS of Belarus, Minsk 220072, Republic of Belarus.
authors.forename: I V
authors.initials: IV
authors.lastname: Zalutskii
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: L A
authors.initials: LA
authors.lastname: Naleskina
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: N Yu
authors.initials: NY
authors.lastname: Lukianova
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: T M
authors.initials: TM
authors.lastname: Yalovenko
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: T V
authors.initials: TV
authors.lastname: Borikun
authors.affiliation: R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
authors.forename: S O
authors.initials: SO
authors.lastname: Sobchenko
authors.affiliation: Institution of Education "Belarusian State University", Minsk 220030, Republic of Belarus.
authors.forename: I V
authors.initials: IV
authors.lastname: Semak
authors.affiliation: State Scientific Institution "Institute of Physiology", NAS of Belarus, Minsk 220072, Republic of Belarus.
authors.forename: V S
authors.initials: VS
authors.lastname: Lukashevich
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015415:Biomarkers; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D007781:Lactoferrin / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D010641:Phenotype
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D004317:Doxorubicin; D007781:Lactoferrin; D002945:Cisplatin